Extracellular Cyclophilin A Augments Platelet-Dependent Thrombosis and Thromboinflammation

Area of Science:

• Biochemistry
• Immunology
• Cardiovascular Research

Background:

• Cyclophilin A (CyPA) plays a role in inflammatory and cardiovascular diseases.
• Existing treatments lack specificity for extracellular CyPA, risking off-target effects.

Purpose of the Study:

• To develop and evaluate a specific antibody inhibitor for extracellular CyPA.
• To assess the therapeutic potential of this inhibitor in models of thrombosis and inflammation.

Main Methods:

• Immunization of mice and rats with a specific peptide to generate antibodies.
• Selection and purification of antibody clones, with clone 8H7-mAb chosen for further study.
• In vitro and in vivo testing of 8H7-mAb for effects on inflammatory cell migration, platelet activation, and thrombus formation.

Main Results:

• The 8H7-mAb specifically binds and inhibits extracellular CyPA.
• 8H7-mAb significantly reduced inflammatory cell migration in vitro and in vivo.
• 8H7-mAb demonstrated potent antithrombotic effects by inhibiting CyPA-dependent platelet activation and thrombus formation.
• Crucially, 8H7-mAb did not affect bleeding time or blood coagulation parameters, preserving blood homeostasis.

Conclusions:

• Antibody-based inhibition of extracellular CyPA is a viable strategy for treating thrombosis and thromboinflammation.
• 8H7-mAb represents a promising therapeutic candidate for modulating thrombi in inflammatory conditions.
• This approach offers targeted therapy for organ dysfunction prevention without compromising hemostasis.